Transcript Highlights:

• This bill allows drug manufacturers to receive licenses prior to FDA product approval.

Summary: The House convened, opened with prayer and the Pledge of Allegiance, welcomed numerous guests and interns to the chamber, and established a quorum with 202 members voting on the master roll call. The House then received committee reports on several bills and a resolution, including measures from Consumer Protection, Finance, Communications and Technology, Rules, and Appropriations, and agreed to the reports. House Bill 1877 was reported as passed by the Senate without amendment and was signed by the Speaker for presentation to the Governor. The chamber adopted House Resolution 363, as amended, directing the Joint State Government Commission to study Pennsylvania’s early childhood education system, including the role of public and private equity in child care and recommendations to improve access and affordability. The House also advanced several bills on final passage, including House Bills 2551, 75, 76, 426, 1127, 2234, and 1585. These measures addressed issues such as banning government text-message collection of fees and tolls, medical licensing for physician assistants and physicians, native habitats at Commonwealth facilities, joining the dental and dental hygienist compact, a spent grain donation tax credit, and restrictions on mugshot removal fees. Most passed with broad support, though House Bill 1127 drew opposition over concerns about licensing standards and the compact structure. Members also considered House Bill 2650, creating the Governor’s Responsible Infrastructure Development Certification for data centers, and House Bill 2496, establishing a temporary pause on data center proposals while local ordinances are reviewed. Both bills were amended several times. Debate on HB 2650 focused on data center impacts on electricity costs, water use, noise, community benefit agreements, and farmland protection; one farmland-protection amendment was tabled, while other amendments on closed-loop cooling and enforceable local criteria were adopted. Debate on HB 2496 centered on preserving local control and home rule authority for municipalities, with amendments clarifying that local governments could continue curative amendment procedures and retain zoning powers. The House agreed to both bills as amended. The House also re-reported several bills from Appropriations and Rules, reconsidered and re-accepted a prior committee report on House Bill 2359, and announced caucus and committee meetings. At the end of the session, the House moved several bills to Appropriations, removed Senate Bill 1058 from the table calendar to the active calendar, and adjourned until Wednesday, June 24, 2026, at 11 a.m., unless recalled sooner.

Transcript Highlights:

• first-in-the-nation commission report documenting conflicts of interest with the wireless industry, the FCC, and the FDA

Keywords: 995, all

Summary: The committee heard testimony on a range of energy, utility, broadband, and municipal infrastructure bills. Representative Powell supported H 3466, which would create a task force to study public ownership of utilities and alternatives to investor-owned electric and gas systems. Representative Therber supported H 3574, which would use RGGI funds to reimburse cities and towns affected by power plant decommissioning, citing lost jobs, tax revenue, and service cuts in communities such as Somerset, Plymouth, Salem, and Everett. Several witnesses from municipal light plants and related organizations testified in support of mutual aid bills, including H 3486/S 2252 and H 3330/S 2277, saying the measures would clarify protections and liability coverage for MLP workers assisting in emergencies and non-emergency work. Jim Leiden of EMWIC opposed H 3514/S 2295, saying the proposed board and governance changes would reduce local control, add burdens, and weaken confidentiality protections. A committee member asked whether the mutual aid bills had been reviewed for municipal impacts, and the witnesses said they had done due diligence. The committee also heard extensive testimony on H 3551/S 2306, the smart meter opt-out bills. Supporters argued that smart meters emit harmful wireless radiation, that some residents have developed health problems or electromagnetic sensitivity, and that opt-outs should be available without fees or penalties; several witnesses urged notification, consent, and non-transmitting analog meter options. The committee also heard testimony from municipal officials and the Massachusetts Municipal Association in support of H 3462/S 2250, which would strengthen municipal authority to enforce timely removal of double utility poles, citing safety, accessibility, and construction-delay concerns. Derek Leffert of Gateway Fiber opposed H 3450, saying it would improperly shift broadband deployment costs to competitors. At the end of testimony, the chair closed the hearing by motion and vote, with members voting aye and no opposition recorded.

Transcript Highlights:

• The bill allows the use Jan Bellamy: not one of which has ever received FDA approval for safety and effectiveness

Keywords: 999, senate, all

Transcript Highlights:

• Fluoridation is a form of a medical treatment recognized by the FDA addressing tooth decay.

Keywords: 999, senate, all

Transcript Highlights:

• and if diagnosed be informed about what resources are available and forms of clinical trials and the FDA

Keywords: 999, senate, all

Transcript Highlights:

• what we need to do is have the legislature work with the feds, work up with Washington, to stop the FDA

Bills: HB154, HB153, HB180, SB70

Keywords: veterans affairs, Alabama Department of Veterans Affairs, State Board of Veterans Affairs, commissioner, governor appointment, board advisory, veteran service organizations, veterans homes, veterans cemeteries, veteran service officers, district managers, state veterans home trust fund, veterans benefits, military veterans, disabled veterans, elderly veterans, active-duty service members, state agency reorganization, executive authority, governance reform

Transcript Highlights:

• This bill permits licensed health care providers to administer ibogaine under the framework of an FDA
• This bill permits licensed health care providers to administer ibogaine under the framework of an FDA

Keywords: 1191, senate, all

Transcript Highlights:

• that's in line with the standard that a drug has to meet, safety and efficacy, to be approved by the FDA
• :11.120> align<01:16:11.679> more<01:16:11.920> with<01:16:12.239> that FDA
• So that would align more with that FDA.
• Um, vaccines, like other FDA-approved medications, go through a series of phase 1 through 3 clinical
• ,<01:27:56.000> go other FDA approved medications, go other FDA approved medications, go through

Keywords: 1191, senate, all

Transcript Highlights:

• FDA-cleared scalp cooling devices are a proven way to help reduce chemotherapy-induced hair loss.
• Denying or delaying an FDA-approved treatment could drive patients into hospital beds, operating rooms
• I called the FDA, and I said, I want to apply for an organic pesticide permit, and they said it's going
• I called the FDA, and I said, I want to apply for an organic pesticide permit, and they said, it's going

Keywords: 988, house, all

Summary: The Assembly convened, first dealing with quorum and routine procedural matters before moving through a series of third-reading bills, many focused on immigration enforcement, worker protections, child care, and school or voting-site safety. Early measures included AB 2393, AB 1994, AB 1929, AB 1633, AB 1650, AB 1655, AB 1851, AB 1896, and AB 2230, with authors and supporters arguing these bills would provide accountability, protect immigrant communities, preserve access to benefits and services, and limit intimidation by immigration enforcement. Opponents repeatedly argued the bills were anti-law-enforcement, unconstitutional, or based on exaggerated or nonexistent threats. Several bills passed by recorded vote, including AB 2393 (41-15), AB 1994 (58-0), AB 1929 (41-17), AB 1650 (44-19), AB 1655 (50-14), AB 1851 (56-0), AB 1896 (41-19), and AB 2230 (42-15). AB 1633, a 54-vote bill imposing a tax on for-profit detention facilities, was debated at length but the roll was not completed in the excerpt and the item was moved on from temporarily. After a caucus break, the House returned and took up additional bills. AB 2379 would require child care providers to be informed of constitutional protections and receive multilingual training regarding immigration enforcement; it passed 59-10 on both the urgency and the measure. AB 2460 would direct the education department to update referral protocols so schools can better respond to students affected by immigration enforcement trauma and family deportation; it passed 52-8. AB 2495 would expand prohibitions on unfair immigration-related practices by employers, making immigration-related threats unlawful in workplace disputes; it passed 50-15. Throughout the day, debate was highly partisan and often heated, with repeated exchanges over whether the bills addressed real harms or were political messaging, but the Assembly ultimately advanced the measures that came to a vote.

Transcript Highlights:

• You need a Schedule I drug license, DEA permissions, and FDA permissions.
• <01:41:42.159> permissions<01:41:42.960> and<01:41:43.440> um<01:41:43.679> FDA
• DEA permissions and um FDA permissions. DEA permissions and um FDA permissions.

Keywords: 958, all

Summary: The committee met and approved the minutes from its August 27 meeting. It then received a presentation from Katherine Castanza of the National Conference of State Legislators on the Medicaid provisions in the 2025 budget reconciliation bill, referred to as HR1. She explained that the bill is estimated by CBO to save the federal government $911 billion over 10 years, with more than 20 Medicaid-specific provisions, most of the savings concentrated in five policies and largely backloaded into 2030-2034. She emphasized that the bill’s effects will vary by state, but that expansion states and hospitals are expected to be most affected, in part because of changes to eligibility, provider taxes, and state-directed payments. Castanza highlighted several new funding and flexibility provisions, including a $50 billion Rural Health Transformation Fund for 2026-2030 and a new home- and community-based services waiver option effective July 1, 2028, with $100 million in grants in fiscal year 2027. She also outlined major eligibility changes for Medicaid expansion adults: work or community engagement requirements effective January 1, 2027; twice-yearly redeterminations for the expansion population effective the same date; and new cost sharing for certain expansion adults effective October 1, 2028. She noted that Kentucky, as an expansion state, would be subject to these changes and that state agencies would face significant implementation demands, especially because federal guidance and timelines are tight. A substantial portion of the presentation focused on financing changes. Castanza described new limits on provider taxes, including a 0% safe harbor for new taxes and a phased reduction for existing taxes in expansion states beginning in 2028, while nursing facilities and intermediate care facilities are exempt from the reduction if already taxed. She also explained that state-directed payments will be capped and phased down over time, with existing arrangements grandfathered only briefly; she said Kentucky has 11 approved state-directed payments and could see significant fiscal effects. She added that the bill also bars Medicaid payments to Planned Parenthood or similarly situated providers for one year, changes immigrant eligibility rules effective October 1, 2026, lowers the federal match for certain emergency services, and expands the scope of the federal erroneous payment recoupment provision effective October 1, 2029. Throughout, she stressed that federal savings may translate into state cost shifts and that implementation timing will be critical.

Transcript Highlights:

• warnings and often mislabeled if they're truly medicine, they should be treated like medicine under FDA
• allowed him to be even in front of several U.S. presidents. shops appear with products that were not FDA
• about 15 I found while I was sitting here while a bunch of others told you that that was not true the FDA
• If these products are considered medicine, then the FDA should be the sole authority in regulating them

Bills: HB 28, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, HB28, public testimony, committee decorum, bill substitute, legislative process

Summary: The meeting featured significant discussions regarding HB28, where the chair outlined the plans to bring forward a substitute for the bill. The chair emphasized the importance of maintaining order and decorum during the proceedings. Members engaged in deliberations, and a number of public witnesses were invited to testify, thereby enriching the discussion around the bill. This interaction provided valuable insights into public sentiment regarding the issues at hand.

Transcript Highlights:

• He also said that as Minnesota enters the era of Alzheimer's treatment, with FDA-approved medications
• He also said that as Minnesota enters the era of Alzheimer's treatment, with FDA-approved medications
• He added that as Minnesota enters the era of Alzheimer's treatment, with FDA-approved medications now
• He said that as Minnesota enters the era of Alzheimer's treatment, with FDA-approved medications now

Bills: HF837, HF1903, HF499, HF794

Keywords: health insurance, premium security plan, federal funding, state innovation waiver, Minnesota, newborn safety, anonymity, healthcare provider, safe place, child welfare, HF499, nursing, nurse licensure, temporary permit, temporary nursing permit, Board of Nursing, endorsement licensure, reregistration, refresher course, health occupations

Transcript Highlights:

• These are FDA-approved drugs that are proven to reduce substance use for opioids.
• disorder so medications for opioid use disorder so these<00:32:48.600> are<00:32:48.760> FDA
• approved<00:32:49.600> drugs<00:32:49.880> that<00:32:50.000> are these are FDA
• approved drugs that are these are FDA approved drugs that are proven<00:32:50.440> to<00:32:50.639

Bills: HF696, HF1429, HF1379

Keywords: HF696, rural EMS, ambulance, emergency medical services, uncompensated care, payment pool, rural health, Office of Emergency Medical Services, public safety answering point, PSAP, nontransport, unpaid ambulance calls, EMS reimbursement, rural ambulance provider, general fund appropriation, Minnesota health finance, specialized life support, metropolitan counties, emergency response funding, HF1429

Transcript Highlights:

• And I said to her, so let me get this straight: so the FDA doesn't regulate any of these things that
• said so let me get this straight<01:43:49.280> so<01:43:49.679> the<01:43:49.840> FDA
• 01:43:50.360> doesn't<01:43:51.080> regulate<01:43:51.560> any straight so the FDA
• doesn't regulate any straight so the FDA doesn't regulate any of<01:43:51.920> these<01:43:52.119

Keywords: 928, house, all

Summary: The committee held a public hearing on HB 733-FN, a bill on third-party litigation financing (TPLF). Representative Cole, the prime sponsor, described TPLF as outside investors financing lawsuits in which they have no personal stake, arguing that the practice is largely unregulated, can involve foreign entities, and contributes to litigation abuse, higher insurance costs, and what he called a “tort tax.” He said the bill is modeled on an NCOIL proposal and would require disclosure of TPLF agreements, with specific references to foreign-entity restrictions, consumer-protection guardrails, and reporting requirements. He also noted a few technical fixes to the draft, including adding the word “knowingly” and restoring a section that had been omitted. Committee members questioned how the bill’s foreign-entity language would work, including whether a governor or the Department of Safety would designate countries of concern, and whether the bill would bar foreign parties from using litigation funding. Cole and others clarified that the bill was intended as a reporting measure, not a ban on litigation funding itself, and that the goal was to disclose who is funding lawsuits and to what extent. Representative Sal asked whether the bill would prevent a litigant from getting outside financing; Cole answered no, emphasizing disclosure rather than prohibition. Brandon Grat of the Attorney General’s Consumer Protection and Antitrust Bureau testified that the bill’s enforcement provisions were too limited. He said the draft appears to give the Attorney General only a civil-penalty remedy, likely too small to deter violations, and not the broader Consumer Protection Act tools such as injunctions, restitution, or investigation authority. He also raised concerns about whether the Attorney General or Insurance Department would have proper jurisdiction, given that the product may be financial or insurance-related. Insurance Commissioner DJ Benton Court said the department sees possible benefits from transparency because disclosure of litigation funding could help insurers assess risk, improve underwriting, and potentially ease hard-market pressures, especially for nonprofits and child care providers. He also said the bill’s language likely needs further work to clarify agency authority and suggested involving the Attorney General, Insurance Department, and banking regulators. Opposition testimony came from the New Hampshire Trial Lawyers Association. Marissa Chase and Samantha Hering argued the bill is one-sided because it requires disclosure only on the plaintiff side and not from defendants or insurers. They said New Hampshire already has court rules and discovery procedures that cover relevant disclosures, making the bill unnecessary, and questioned whether the existence of a funding contract is even relevant in litigation. The hearing ended with the committee continuing to discuss possible revisions and enforcement options, but no vote or final action was taken in the transcript.

Transcript Highlights:

• And I said to her, so let me get this straight: so the FDA doesn't regulate any of these things that
• said so let me get this straight<01:43:49.280> so<01:43:49.679> the<01:43:49.840> FDA
• 01:43:50.360> doesn't<01:43:51.080> regulate<01:43:51.560> any straight so the FDA
• doesn't regulate any straight so the FDA doesn't regulate any of<01:43:51.920> these<01:43:52.119

Keywords: 928, house, all

Summary: The committee heard testimony on HB 733-FN, a bill concerning third-party litigation financing (TPLF). Representative Cole, the prime sponsor, described TPLF as outside investors funding lawsuits in which they have no personal stake, arguing that the practice is largely unregulated, can involve foreign entities, increases litigation abuse, and contributes to higher insurance and consumer costs. He said the bill is modeled on an NCOIL proposal and would require disclosure of TPLF agreements, with guardrails and reporting requirements on specified pages of the bill. He also noted a couple of drafting fixes, including adding the word “knowingly” and incorporating a missing section later. Members raised questions about the bill’s foreign-entity language, especially the provision allowing a governor or the Department of Safety to designate a country as a threat to critical infrastructure. Representative Cole said he would have lawyers review that issue. Another member asked whether the bill would prohibit a party from obtaining outside funding for a lawsuit; Cole clarified that the bill is intended as a reporting measure, not a ban, and that disclosure would be required. He also said the bill is aimed at American citizens rather than foreign-backed financing, and that some states had considered caps on such arrangements, though this bill does not. Brandon Gratz of the Attorney General’s office testified that the enforcement language appears too limited, because it would allow only civil penalties and not broader Consumer Protection Act remedies such as injunctions or restitution. He suggested the Attorney General may not have meaningful authority under the bill as written and raised possible insurance-law issues. Commissioner D.J. Benton-Court of the Insurance Department said the disclosure could help insurers better assess risk and potentially soften the hard insurance market by improving transparency, competition, underwriting, innovation, and claims management. He also said the bill likely needs further work on jurisdiction and enforcement, and that the committee may need to coordinate with the Attorney General, Insurance Department, and possibly banking regulators. No vote was taken in the portion provided.

Transcript Highlights:

• In 2024, the FDA approved the first investigational new drug for an induced pluripotent cell.
• uh<01:20:58.800> in<01:20:58.920> 2024<01:20:59.719> the<01:20:59.800> FDA
• <01:21:00.239> approved<01:21:00.960> first 2022 uh in 2024 the FDA approved first
• 2022 uh in 2024 the FDA approved first indd<01:21:02.400> uh<01:21:02.600> investigational<

Keywords: 1183, house

Summary: The House Higher Education Finance and Policy Committee met and approved the minutes from the previous meeting. The chair noted that agency overviews from the Office of Higher Education and other state agencies were not available, so the committee proceeded with University of Minnesota presentations instead. The committee also reviewed posted committee rules. University of Minnesota representatives gave an overview of the university’s research enterprise, describing it as a system of five campuses with a possible expansion to St. Cloud, and highlighting research strengths across campuses in agriculture, energy, natural resources, health, and the Twin Cities flagship campus. They said the university has more than $1.3 billion in annual research expenditures, receives most of its research funding from federal sources, and is ranked highly for both overall research and interdisciplinary research. Examples discussed included the Clinical and Translational Science Institute, the Forever Green initiative, and research tied to sustainable crops, health, and commercialization. Members asked questions about specific research areas, including biodegradable or renewable plastics, wheat research, food dyes, health and environmental toxins, and the market for winter camelina and winter pennycress. University staff said they could follow up with more detailed information and explained that the winter crop work is intended to become market-driven over time, while also improving soil health and creating new revenue streams for farmers. They also clarified that the university’s federal research funding includes money from NIH, NSF, DOE, DOD, and other agencies, and that the “other” funding category includes foundations, subawards, and internal university seed funding. The committee then heard a second University of Minnesota presentation focused on partnerships, commercialization, and workforce development. Testimony highlighted collaborations with industry and government partners such as U.S. Steel, 3M, Medtronic, Cisco, and defense-related industry leaders, as well as programs supporting microelectronics, AI, cybersecurity, and sustainable aviation fuels. No formal votes were taken beyond approving the minutes, and the committee ended the segment by moving on to the next testifier.

Transcript Highlights:

• So it actually starts at the federal level with FDA approval, and then there's a committee out of the
• So it actually starts at the federal level with FDA approval, and then there's a committee out of the
• /c> actually starts at the federal level actually starts at the federal level with<00:26:50.200> FDA
• approval and then there's a with FDA approval and then there's a committee<00:26:52.679> out<
• So, the Department of Health, as I explained earlier, the FDA approves vaccines.

Keywords: 928, house, all

Summary: The committee held a public hearing on House Bill 233, which would impose transparency and reporting requirements on the New Hampshire Vaccine Association. The prime sponsor, Representative Comto, said the bill and a proposed amendment were intended to increase public access by requiring a physical meeting location, making meetings available online, and publishing a complete list of vaccines and pharmaceutical products purchased. She argued the association should be more transparent because it is involved in vaccine purchasing and public trust is important, especially given controversy around vaccines. Committee members questioned the sponsor about the association’s legal status, who sets vaccine requirements, whether other private entities would be covered, and whether the proposal should instead apply more broadly to all meetings or include recordings. The sponsor said the association was created by the legislature, that childhood vaccine requirements come from DHHS and CDC-related processes, and that she would be open to broader recording requirements. Some members raised concerns about misinformation and whether requiring answers to public questions could be problematic in a contentious policy area. Patrick Miller, executive director of the Vaccine Association, and attorney Mark McHugh testified in opposition. They described the association as a not-for-profit voluntary corporation created by statute in 2002 to serve as a funding mechanism for the state’s universal childhood vaccine purchase program, with no policymaking role and no public funding. They said the association already posts notices, agendas, minutes, and allows public webinar access and comments, while also providing annual audits and reports and other statutory reporting. They argued HB 233 would impose unnecessary administrative costs on a private entity, interfere with its limited charitable purpose, and ultimately increase costs borne by insurers, employers, and consumers. No vote or final action was taken during the hearing.

Bills: HB2118, HB1764, HB1815, HB2117, HB2436, HB2438, HB2532, HB2566, HB2573, HB1736, HB2425, HB1590, HB1913, HB1573, HB1542, HB1804, HB1976, HB1704, HB1996, HB1541, HB1926, HB1703, HB1866, HB1710

Keywords: business development, arts, cultural affairs, Hawaii, commissions, administrative transfer, funding appropriation, music education, public concerts, Hawaii State Library, cultural collaboration, music accessibility, State Foundation on Culture and the Arts, SFCA, Performing Arts Grants Program, arts grants, culture and the arts, history and the humanities, King Kamehameha Celebration Commission, Works of Art Special Fund

Bills: HB2118, HB1764, HB1815, HB2117, HB2436, HB2438, HB2532, HB2566, HB2573, HB1736, HB2425, HB1590, HB1913, HB1573, HB1542, HB1804, HB1976, HB1704, HB1996, HB1541, HB1926, HB1703, HB1866, HB1710

Keywords: business development, arts, cultural affairs, Hawaii, commissions, administrative transfer, funding appropriation, music education, public concerts, Hawaii State Library, cultural collaboration, music accessibility, State Foundation on Culture and the Arts, SFCA, Performing Arts Grants Program, arts grants, culture and the arts, history and the humanities, King Kamehameha Celebration Commission, Works of Art Special Fund

Transcript Highlights:

• For example, you will note that the FDA does not review indications for individual drugs on an annual
• c><01:16:10.080> for<01:16:10.159> example,<01:16:10.560> the<01:16:10.719> FDA
• I mean, for example, the FDA will respond if there is compelling new information.
• At the federal level, institutional review boards operating under FDA regulations are required to review
• At the federal level, institutional review boards operating under FDA regulations are required to review

Keywords: 1191, senate, all